Advanced NanoTherapies

Summary active Updated Jun 3, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Location Sunnyvale, California
Founded 2010
Latest Stage Series B
Total Raised $31M+ (Series B)

About

Advanced NanoTherapies (ANT) is a clinical-stage medtech company focused on improving outcomes for patients with coronary and peripheral artery disease 12. The company is developing SirPlux Duo, a dual-drug nanoparticle-coated balloon (DCB) platform that uses a proprietary nanoparticle delivery system to drive active cellular uptake within the vessel wall, combining sirolimus and paclitaxel — two proven antiproliferation agents 13. ANT has clinical experience across two coronary studies and a defined U.S. regulatory path toward pivotal execution 2.

Funding History

Date Round Amount Lead Co-investors
2026-06-02 Series B $31M+ S3 Ventures, undisclosed strategic investor T45 Fund, other new and existing investors 123

The oversubscribed Series B will fund continued clinical development of SirPlux Duo and preparation for pivotal trials 12.

What Investors Say

Brian R. Smith, Managing Director at S3 Ventures, stated: “This financing validates the strength of ANT’s platform and the momentum built across science, clinical execution, and regulatory readiness. With clinical experience across two coronary studies and a clear U.S. regulatory path, ANT is well positioned to move toward pivotal execution and to bring a truly differentiated therapy to patients needing better options.” 12

What Founders Say

No independently sourced founder quotes available at the time of profile creation.

Sources


  1. “Advanced NanoTherapies Secures Over $31M Series B to Deliver First-of-its-Kind Dual-Drug (Paclitaxel and Sirolimus) Nanoparticle-Coated Balloon Platform for Vascular Treatment,” PR Newswire, June 2, 2026. https://www.prnewswire.com/news-releases/advanced-nanotherapies-secures-over-31m-series-b-to-deliver-first-of-its-kind-dual-drug-paclitaxel-and-sirolimus-nanoparticle-coated-balloon-platform-for-vascular-treatment-302786565.html (accessed June 2026) 

  2. “Advanced NanoTherapies raises $31M for drug-coated balloon tech,” MassDevice, June 2026. https://www.massdevice.com/advanced-nanotherapies-raises-31m-dcb/ (accessed June 2026) 

  3. “Advanced NanoTherapies secures over US$31 million Series B to deliver dual-drug nanoparticle-coated balloon platform,” Vascular News, June 2026. https://vascularnews.com/advanced-nanotherapies-secures-over-us31-million-series-b-to-deliver-dual-drug-nanoparticle-coated-balloon-platform/ (accessed June 2026)